Kaleido Biosciences, Inc.
KLDODelisted Apr 18, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001751299
Kaleido Biosciences, Inc. was delisted on Apr 18, 2022; its insiders filed their last Form 4 on Mar 2, 2022; 63 institutions reported holding it in 13F filings for Q1 2022, worth $55.1M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:10 PM ET
Revenue flow, FY2021
Where the revenue went in FY2021, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2021: $90.3M (8178.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | Mar 3, 2021 | Mar 2, 2020 |
| Revenue | $1.10M | $975.0K | – |
| Operating expenses | $88.8M | $79.8M | $86.7M |
| Research and development | $67.8M | $56.0M | $64.2M |
| Selling, general and administrative | $21.0M | $23.9M | $22.4M |
| Operating income | -$87.7M | -$78.9M | -$86.7M |
| Interest expense | $2.84M | $2.80M | $977.0K |
| Income tax | – | $0 | $0 |
| Net income | -$90.3M | -$81.6M | -$86.3M |
| Margins and growth | |||
| Operating margin | -7940.9% | -8089.6% | – |
| Net margin | -8178.3% | -8371.3% | – |
| Revenue growth, year over year | +13.2% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | Mar 3, 2021 | Mar 2, 2020 |
| Cash and equivalents | $38.5M | $46.2M | $71.2M |
| Total current assets | $42.3M | $48.7M | $73.3M |
| Property, plant and equipment | $5.67M | $8.46M | $6.74M |
| Total assets | $50.1M | $59.3M | $82.3M |
| Accounts payable | $5.67M | $5.39M | $2.02M |
| Short-term debt | $16.1M | $2.63M | – |
| Total current liabilities | $29.7M | $16.7M | $10.4M |
| Long-term debt | $5.55M | $18.4M | $20.4M |
| Total liabilities | $39.5M | $38.8M | $33.4M |
| Shareholders' equity | $10.6M | $20.5M | $48.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | Mar 3, 2021 | Mar 2, 2020 |
| Operating cash flow | -$77.1M | -$61.5M | -$75.8M |
| Capital expenditures | $1.13M | $4.02M | $3.59M |
| Free cash flow | -$78.2M | -$65.5M | -$79.4M |
| Depreciation and amortization | $2.40M | $1.80M | $1.32M |
| Stock-based compensation | $10.3M | $12.7M | $10.1M |
| Investing cash flow | -$691.0K | -$4.02M | -$3.59M |
| Financing cash flow | $70.0M | $40.4M | $74.6M |
| Net change in cash | -$7.75M | -$25.1M | -$4.74M |
| Ratio | |||
| Stock-based compensation, % of revenue | 936.8% | 1300.9% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Mar 31, 2022 | 42.6M | +0.2% | SEC |
| Oct 29, 2021 | 42.6M | +18.4% | SEC |
| Aug 9, 2021 | 42.6M | +19.8% | SEC |
| Apr 30, 2021 | 42.5M | +39.4% | SEC |
| Feb 26, 2021 | 42.5M | +39.6% | SEC |
| Oct 30, 2020 | 36.0M | +19.7% | SEC |
| Jul 31, 2020 | 35.5M | +19.2% | SEC |
| May 7, 2020 | 30.5M | +2.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.